ABBV: EU Approves MAVIRET
AbbVie's MAVIRET is approved by the European Commission for people with acute Hepatitis C Virus infection
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ABBV: MAVIRET Approved
AbbVie's MAVIRET is approved by the European Commission for acute HCV infection, becoming the only EU-approved treatment for both acute and chronic Hepatitis C Virus infection